Patanase generic
Patanase is an antiallergic drug owned by Novartis that contains the active ingredient olopatadine hydrochloride. Patanase was first approved for use on 15 April, 2008 and is available in spray, metered;nasal dosage forms.
When will Patanase generic be available?
The generics of Patanase are expected to become available after 2 August, 2023. This is due to the expiration of the last patent, US7977376*PED, on this date.
Patanase uses
Patanase is used primarily for the treatment of allergic rhinitis. Its effectiveness is derived from its active ingredient, olopatadine hydrochloride, which works by blocking histamine and subsequently suppressing the allergic symptoms.
Patanase patent expiration
Patanase is protected by 4 patents, with the last one, patent US7977376*PED, set to expire on 2 August, 2023. This implies that the Patanase generic could potentially be available after this date. Below are the details of the patents: